Medlab Clinical : Presenting at Jefferies London Healthcare Conference

For personal use only

ASX ANNOUNCEMENT

MEDLAB PRESENTS AT THE JEFFERIES LONDON HEALTHCARE CONFERENCE

SYDNEY, November 16, 2021 - Medlab Clinical Ltd (ASX: MDC) a delivery platform development company, is pleased to announce that it is presenting at the Jefferies London Healthcare Conference starting today and concluding Friday 19 November 2021.

During the 30-minute Presentation, Medlab outlines both its near-term goals and program optix. A Summary presentation is attached to this announcement.

Dr Sean Hall, CEO of Medlab says "we have had an overwhelming response for initial partnering discussions, all of which represent new opportunities, and from a cursory view, appears driven from the granting of NanoCelle® patents."

Medlab will offer a presentation replay at 12:00pm on Monday 22nd November 2021 (AEDT). To register for this 30-minute webinar, please register here.

ENDS

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab Clinical:

Medlab Clinical Ltd (ASX: MDC) is pioneering the development and commercialisation of a pharmaceutical delivery platform, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis™ has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non- cancer neuropathic pain. NanoCelle®, the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR (Office of the Gene Technology Regulator) Registered Laboratory. NanoCelle® is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK. For more information, please visit www.medlab.co

Medlab - better medicines, better patient care

Medlab Clinical	Medlab US Investor Relations
Mr Kerem Kaya, CFO
T: [phone]	Laine Yonker
[e-mail]	[e-mail]

Medlab Clinical Limited, 66 McCauley St, Alexandria NSW 2015

P: [phone] F: [phone] W: www.medlab.co

onlyuse ersonalC ntact Us

MEDLAB CLINICAL LTD

Summary of Video Presentation for

Jefferies London Healthcare Conference

November 2021

Presenters:

Dr Sean Hall | CEO & Managing Director

Prof. Luis Vitetta | Director of Medical Research

Dr Jeremy Henson | Medical Affairs Director

Dr Michelle Quezada | Research & Development Technical Scientist

Mr Kerem Kaya | CFO

ASX:MDC

Scientifically optimised for a better life

WHO IS MEDLAB

Medlab Clinical Ltd (ASX:MDC) is an Australian Biotech specialising in delivery platforms. Medlab is undertaking development for several drug registrations and pursuing revenue partnering opportunities.

COMMERCIAL APPROACH

Exploring Variety of

Partnering Models

Royalties, Joint Ventures &

Asset Sales

only
NanoCelle®
Delivery Platform
	•
	•
use	•
ersonal

NanoCBD™

T rgeting Stress

•

•

•

•

Proprietary, patented delivery platform.

Several branded molecules moving through clinical evidence for drug registration.

Partnering underway for multiple different molecules.

Enhanced by NanoCelle® delivery platform

TGA Pathway understood for OTC registered Medicine.

Similar to NanaBis™ - without THC.

In Partnering Discussions.

NanaBis™

Targeting cancer bone pain

• Enhanced by NanoCelle® delivery platform
• Safe, Tolerable, Efficacious.
• PI/II Complete - 900+ AU patients under clinical observation.
• Preparing for N=360 AU, UK & US PIII - (Estimated May 2022).
• NDA Estimated 2024.
• DMF for CBD & THC, working on robust CMC.
• In partnering discussions.

Nutraceuticals

• Divested AU operational Model.
• Medlab reserves Global rights and ownership of R&D and IP and ability for future licencing.
• Pursuing global trade opportunities.

Expanding Global
Leadership Team	Securing US & AU
Worldwide Presence	Grants
Increased IR Focus

	In House
48 Global Patents	Commercialisation
Teams
	Global BD & MSL Teams

Click or scan to watch Medlab Channel 7 Interview

P.2

Scan QR Code to email us with any questions, or email us [e-mail]

INVESTMENT HIGHLIGHTS

• Patented NanoCelle® drug delivery platform with total addressable market of platform is $260 Billion

• Partnering activities underway globally offering
only
	near term and future revenue
• Portfolio of	therapeutics,	including cannabinoid
	therapeutics	addressing	global unmet need in
	ncology areas including pain management;
	transitioning to synthetic APIs in accordance with
	regulatory guidance
use
•	Lead candidate NanaBis™ met Phase I/II primary
	and secondary endpoints in bone cancer patients,
	RWE continues to provide strong, positive signals,
	prepping for global P3
• Strong global patent portfolio.
ersonal
•	Experienced Board and Management team with

>150 years combined experience in the life sciences space; experience at Novartis, Abbott, Sanofi and Medlab among others

STRONG MOMENTUM IN 2021

NOV 21	NanoCelle® US Patent Granted
NOV 21	PharmaCare purchases Medlab's AUS Nutraceutical Business
OCT 21	Orotate US Patent Granted
OCT 21	NanoCelle® issued notice of allowance by US patent office
AUG 21	NanaBis™ Phase III Trials approved in Australia
JUL 21	Master Services Agreement (MSA) in UK - NanaBis™
JUL 21	Granted Ethics for NanaBis™ Phase III Trials in Australia
JUL 21	Strong NRGBiotic™ results achieved
JUN 21	Europe & Canada NanoCelle® patent granted
MAY 20	Synthetic introduction to phase III NanaBis™ announced
NOV 20	UK NanaBis™ NIHR Trial collaboration
JUN 20	Australian NanoCelle® Patent Granted

P.3

EXECUTIVE AND MANAGEMENT TEAM

only	Prof Luis Vitetta	Dr Patrick Miller
use	BSc (Hons), PhD, MD, GradDip	Director of Pharmacovigilance
Nutr/Environ Med, Grad Dip Integ Med	& Regulatory Affairs
ersonal	Director of Medical Research
Tony Potter	Dr Jeremy Henson
	BSc (Hons), Dip Management	MBBS PhD BSc (Hons) Medical
	GM Pharma, Commercialisation	Affairs Director
	& Education

Kerem Kaya	Ian Curtinsmith
Chief Financial Officer &	Chief Information Officer
Company Secretary

Dr David Rutolo, Jr.,

PhD, JD, Director of Science

P.4